Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 16:1-14.
doi: 10.1007/s40121-021-00475-x. Online ahead of print.

In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients

Raquel Rubio-Acero #  1 , Noemi Castelletti #  1   2 , Volker Fingerle  3   4 , Laura Olbrich  1   3 , Abhishek Bakuli  1 , Roman Wölfel  3   5 , Philipp Girl  3   5 , Katharina Müller  3   5 , Simon Jochum  6 , Matthias Strobl  6 , Michael Hoelscher  1   3   7 , Andreas Wieser  1   3 ; KoCo19 study team
Collaborators, Affiliations

In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients

Raquel Rubio-Acero et al. Infect Dis Ther. .

Abstract

Background: Quantitative serological assays detecting response to SARS-CoV-2 are needed to quantify immunity. This study analyzed the performance and correlation of two quantitative anti-S1 assays in oligo-/asymptomatic individuals from a population-based cohort.

Methods: In total, 362 plasma samples (108 with reverse transcription-polymerase chain reaction [RT-PCR]-positive pharyngeal swabs, 111 negative controls, and 143 with positive serology without confirmation by RT-PCR) were tested with quantitative assays (Euroimmun Anti-SARS-CoV-2 QuantiVac enzyme-linked immunosorbent assay [EI-S1-IgG-quant]) and Roche Elecsys® Anti-SARS-CoV-2 S [Ro-RBD-Ig-quant]), which were compared with each other and confirmatory tests, including wild-type virus micro-neutralization (NT) and GenScript®cPass™. Square roots R of coefficients of determination were calculated for continuous variables and non-parametric tests were used for paired comparisons.

Results: Quantitative anti-S1 serology correlated well with each other (true positives, 96%; true negatives, 97%). Antibody titers decreased over time (< 30 to > 240 days after initial positive RT-PCR). Agreement with GenScript-cPass was 96%/99% for true positives and true negatives, respectively, for Ro-RBD-Ig-quant and 93%/97% for EI-S1-IgG-quant. Ro-RBD-Ig-quant allowed distinct separation between positives and negatives, and less non-specific reactivity versus EI-S1-IgG-quant. Raw values (95% CI) ≥ 28.7 U/mL (22.6-36.4) for Ro-RBD-Ig-quant and ≥ 49.8 U/mL (43.4-57.1) for EI-S1-IgG-quant predicted NT > 1:5 in 95% of cases.

Conclusions: Our findings suggest both quantitative anti-S1 assays (EI-S1-IgG-quant and Ro-RBD-Ig-quant) may replace direct neutralization assays in quantitative measurement of immune protection against SARS-CoV-2 in certain circumstances. However, although the mean antibody titers for both assays tended to decrease over time, a higher proportion of Ro-RBD-Ig-quant values remained positive after 240 days.

Supplementary information: The online version contains supplementary material available at 10.1007/s40121-021-00475-x.

Keywords: COVID-19; Direct virus neutralization assay S1; Quantitative serology; SARS-CoV-2.

PubMed Disclaimer

References

    1. Int J Environ Res Public Health. 2021 Mar 30;18(7): - PubMed
    1. Rev Med Virol. 2020 May;30(3):e2106 - PubMed
    1. J Clin Virol. 2020 Aug;129:104468 - PubMed
    1. Biochem Biophys Res Commun. 2021 Jan 29;538:187-191 - PubMed
    1. Lancet Infect Dis. 2020 Dec;20(12):1390-1400 - PubMed

LinkOut - more resources